dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639–1647.OpenUrlAbstract/FREE Full Text 29. 29.↵ 1. Meany H, 2. Balis FM, 3. Aikin A, 4. et al .Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010;102:909–912.OpenUrlCrossRefPubMed 30. 30.↵ 1
tumor selectivity and long tumor retention, which may be a better-match with therapeutic radionuclides (e.g.,Lu, Ac) for cancer therapy. Here we report a Lu-labeled anti-FAP antibody, PKU525, as a therapeutic radiopharmaceutical for FAP-targeted radiotherapy. The anti-FAP antibody is produced as a derivative of sibrotuzumab. The pharmacokinetics and blocking study are performed with Zr-labeled
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. The purpose of this research was to determine the safety, immunogenicity, pharmacokinetics, biodistribution, and tumor uptake of repeat infusions of a complementarity-determining region grafted humanized antibody (sibrotuzumab) directed against human fibroblast activation protein (FAP). A Phase I open-label dose escalation study was conducted in patients with cancers epidemiologically known to be FAP positive. Patients were entered into one of four dosage tiers of 5, 10, 25, or 50 mg/m(2) sibrotuzumab, administered weekly for 12 weeks, with trace labeling with 8-10 mCi of (131)I in weeks 1, 5, and 9. A total of 26 patients were entered into the trial (15 males
Criteria Contacts and Locations More Information Brief Summary: Study to evaluate the anti-tumour activity, safety and pharmacokinetics of unlabelled sibrotuzumab administered weekly (seven days +/- one day) at a dose of 100 mg (a total of 12 administrations) in patients with metastatic colorectal cancer.Condition or disease Intervention/treatment Phase Colorectal Neoplasms Drug: BIBH 1 Arms and Interventions Go to Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Arm Intervention/treatment Experimental: BIBH 1 Drug: BIBH 1100 mg/weekOther Name: Sibrotuzumab Outcome Measures Go to Top of Page Study Description Study Design Arms
Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer - Full Text View - ClinicalTrials.gov Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort. Hide glossary GlossaryStudy DetailSaved Studies Save this study WarningYou have reached the maximum number of saved studies (100).Please remove one or more studies before adding more. Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does